Part,  Chapter, Paragraph

  1    I,     2. 10.  3    |        innovation for the uptake of R&D.~Launching of a public
  2    I,     2. 10.  4    |           proprietary solutions and R&D resources can be created
  3    I,     2. 11        |      Suhrcke M, McKee M, Sauto Arce R, Tsolova S, Mortensen J (
  4   II,     4.  3        |            3. References~ ~Anderson R, Kochanek K, et al. (1997):
  5   II,     5.  2.  6    |          values <120/80 mmHg (Vasan R et al, 2001). Also an isolated
  6   II,     5.  2.  6    |           Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol
  7   II,     5.  2.  6    |         Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment
  8   II,     5.  2.  6    |            Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (
  9   II,     5.  2.  6    |           1278.~Lewington S, Clarke R, Qizilbash N, Peto R, Collins
 10   II,     5.  2.  6    |         Clarke R, Qizilbash N, Peto R, Collins R (2002): Prospective
 11   II,     5.  2.  6    |        Qizilbash N, Peto R, Collins R (2002): Prospective Studies
 12   II,     5.  2.  6    |           HW, Van Buchem FS, Buzina R, Djordjević BD, Dontas AS,
 13   II,     5.  2.  6    |     Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J,
 14   II,     5.  2.  6    |         Halsey J, Qizilbash N, Peto R, Collins R (2007): Prospective
 15   II,     5.  2.  6    |        Qizilbash N, Peto R, Collins R (2007): Prospective Studies
 16   II,     5.  2.  7    |           Manheim LM, Dyer AR, Wang R, Lubitz J et al (2005):
 17   II,     5.  2.  7    |        Ferrario M, Chiodini P, Sega R, and Stamler J (2006): Favorable
 18   II,     5.  2.  7    |        Mattiello A, Pilotto L, Sega R, Giampaoli S, Stamler J (
 19   II,     5.  2.  7    |            Leal J, Luengo-Fernandez R and Gray A (2005): European
 20   II,     5.  3.  7    |      SWITZERLAND~Yes~Source: Haward R, Borras MJ (2007)~ ~ ~Important
 21   II,     5.  3.  9    |               Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota
 22   II,     5.  3.  9    |          592.~ ~Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino
 23   II,     5.  3.  9    |           Specific Issues.~ ~Haward R, Borras MJ (2007): Portuguese
 24   II,     5.  3.  9    |        Quinn M, Mugno E, Capocaccia R, Grosclaude P, and the EUROCARE
 25   II,     5.  3.  9    |               Micheli A, Capocaccia R, Martinez C, Mugno E, Coebergh
 26   II,     5.  3.  9    |            Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani
 27   II,     5.  4.  8    |            P, Battlogg, K, Gfrerer, R, Trajanoski, Z, Wach, P,
 28   II,     5.  4.  8    |             AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT,
 29   II,     5.  5.Int(15)|             ME, Delespaul P, Fuhrer R, Hooijer C, Lawlor BA, Kivela
 30   II,     5.  5.  1    |           MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H (2004a).
 31   II,     5.  5.  1    |       Bernert S, Brugha T, de Graaf R, Bruffaerts R, Lépine JP,
 32   II,     5.  5.  1    |              de Graaf R, Bruffaerts R, Lépine JP, de Girolamo
 33   II,     5.  5.  1    |   Psychiatry 6(3):168-76.~ ~Kessler R, Nelson C, McGonagle K, Liu G (
 34   II,     5.  5.  2    |         2008)~ ~Haan MN and Wallace R (2004): Can dementia be
 35   II,     5.  5.  3    |             10.1002/eat.1022.~Levey R (2006): Anorexia Nervosa.
 36   II,     5.  5.  3    |          Currie CR, Morgan A, Smith R, Settertobulte W, Samdal
 37   II,     5.  5.  3    |          ahead of print.~Bottlender R (2006): For and against: “
 38   II,     5.  5.  3    |          Rossi G, Ghilardi A, Pioli R (2007): The stigma of schizophrenia
 39   II,     5.  5.  3    |          Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet
 40   II,     5.  5.  3    |          Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen
 41   II,     5.  5.  3    |       Wagner M, Maier W, Bottlender R, Möller HJ, Gaebel W, Wölwer
 42   II,     5.  5.  3    |          Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards
 43   II,     5.  5.  3    |        Tranter R, Gutting P, Austin R, Jones-Edwards G, Roberts
 44   II,     5.  5.  3    |         McGraw-Hill Education.~Kohn R, Saxena S, Levav I, Saraceno
 45   II,     5.  5.  3    |             A, Schürmann A, Michels R, Malchow CP, Dilling H (
 46   II,     5.  5.  3    |             333, 2007.~htt df~Vauth R (2006): Psychosocial Interventions
 47   II,     5.  5.  3    |           suppl. 10)~Knapp M, Romeo R, Beecham J (2007): The economic
 48   II,     5.  5.  3    |             63:1002-1007.~Sidenvall R, Forsgren L, Blomquist HK,
 49   II,     5.  5.  3    |        Paediatr 82:60-65.~Sidenvall R, Forsgren L, Heijbel J (
 50   II,     5.  5.  3    |            L, Tonon C, DAlessandro R, on behalf of the Bologna
 51   II,     5.  5.  3    |             Sudomoina M, Turetskaya R (1995): Epidemiology of
 52   II,     5.  5.  3    |          Myhr KM, Nyland H, Midgard R (2004): Multiple sclerosis
 53   II,     5.  5.  3    |         Psychiatry 73;256-260.~Doll R, Hill AB (1966). Mortality
 54   II,     5.  5.  3    |        Gerry E, Johnson M, Williams R (2002). A prospective study
 55   II,     5.  5.  3    |             B, Lemesle M, Urbinelli R, Giroud M (2000): Incidence
 56   II,     5.  5.  3    | Fernández-Buey N, Fernández-Herranz R (1999): Prevalence of multiple
 57   II,     5.  5.  3    |          Neurol 246:170-174.~Totaro R, Marini C, Cialfi A, et
 58   II,     5.  5.  3    |             De Hooghe MB, Vlietnick R, Carton H (1994): Prevalence
 59   II,     5.  5.  3    |              WHO, Geneve.~Zivadinov R, Iona L, Monti-Bragadin
 60   II,     5.  5.  3    |     Rodriguez J, Molina JA, Gabriel R, Morales JM (2003): Prevalence
 61   II,     5.  5.  3    |             345.~Bermejo F, Gabriel R, Vega S, Morales JM, Rocca
 62   II,     5.  5.  3    |            2):242-249.~DAlessandro R, Gamberini G, Granieri E,
 63   II,     5.  5.  3    |            Singer M, Koehne-Volland R, Szucs T, Rathay B, Scholz
 64   II,     5.  5.  3    |           Dorsey ER, Constantinescu R, Thompson JP, Biglan KM,
 65   II,     5.  5.  3    |           MA, Morris JG, Traficante R, Reid WG, OSullivan DJ,
 66   II,     5.  5.  3    |            JG, Reid WG, Trafficante R (2005): Sydney Multicenter
 67   II,     5.  5.  3    |         Spottke E, Siebert U, Dodel R (2005): Cost of Parkinson’
 68   II,     5.  5.  3    |            534-536.~Nath U, Thomson R, Wood R, Ben-Shlomo Y, Lees
 69   II,     5.  5.  3    |             Nath U, Thomson R, Wood R, Ben-Shlomo Y, Lees A, Rooney
 70   II,     5.  5.  3    |             P, Trenkwalder C, Dodel R, Wittchen HU (2008): Cognitive
 71   II,     5.  5.  3    |             Pinna L, Aiello I, Tola R, De Bastiani P, Pirisi A,
 72   II,     5.  5.  3    |            Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter
 73   II,     5.  5.  3    |             Oertel WH, Ulm G, Dodel R (2005): Cost of illness
 74   II,     5.  5.  3    |            836.~Sutcliffe RL, Prior R, Mawby B, McQuillan WJ (
 75   II,     5.  5.  3    |  Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe
 76   II,     5.  5.  3    |          Siebert U, Berger K, Dodel R (2005): Prevalence and incidence
 77   II,     5.  6.  6    |            6.6. References~ ~Altman R, Asch E, Bloch D, Bole G,
 78   II,     5.  6.  6    |      Christy W, Cooke TD, Greenwald R, Hochberg M, . (1986) Development
 79   II,     5.  6.  6    |            PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC (2000):
 80   II,     5.  6.  6    |            878-882~Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld
 81   II,     5.  6.  6    |             J, Pearson N, Greenwood R, Frankel S (2003): Population
 82   II,     5.  6.  6    |       Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG,
 83   II,     5.  6.  6    |        Albertson G, Price D, Swaney R, Anderson S, Anderson RJ (
 84   II,     5.  6.  6    |             Purdie D, Reid DM, Rowe R, Woolf AD, Wallace WA (2001):
 85   II,     5.  6.  6    |            Feeney A, Head J, Canner R, North F, Marmot M (1995):
 86   II,     5.  6.  6    |           Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt
 87   II,     5.  7.  7    |           Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli
 88   II,     5.  7.  7    |             FW, Boersma C, de Vries R, Hillege HL, van Gilst WH,
 89   II,     5.  7.  7    |          Van VJ, Klebe B, Middleton R, et al (2007): Chronic kidney
 90   II,     5.  8.  7    |        Hedlund U, Nilsson T, Flodin R, and Järvholm B (2004):
 91   II,     5.  8.  7    |       Marinoni A, Viegi G, de Marco R (2003): Chronic cough and
 92   II,     5.  8.  7    |             M, Aldington S, Beasley R (2006): Epidemiology and
 93   II,     5.  8.  7    |            27: 188-207.~ ~Dal Negro R, Rossi A, Cerveri I (2003):
 94   II,     5.  8.  7    |              97: s43-50.~ ~De Marco R, Accordini S, Cerveri I,
 95   II,     5.  8.  7    |            in Europe”. Loddenkemper R, Gibson GJ, Sibille Y eds.
 96   II,     5.  8.  7    |      Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E,Nieminen
 97   II,     5.  8.  7    |             AC, Ronmark E, Lundgren R, Larsson LG, Lundback B (
 98   II,     5.  8.  7    |       Heaney L, Gingles J, Shepherd R, Kee F, Patterson C, MacMahon
 99   II,     5.  8.  7    |          Kromhout H, Garcia-Esteban R, Radon R, Jarvis D, Toren
100   II,     5.  8.  7    |             Garcia-Esteban R, Radon R, Jarvis D, Toren K, Künzli
101   II,     5.  9. FB    |        References~ ~Plumb J, Brawer R, Brisbon N (2007): The interplay
102   II,     5.  9.  7    |                Anderson HR, Ruggles R, Strachan DP, Austin JB,
103   II,     5.  9.  7    |   10S73-10S75~ ~Bousquet PJ, Hooper R, Kogevinas M, Jarvis D,
104   II,     5.  9.  7    |            111(2):402-7.~ ~De Marco R (2002): Incidence and remission
105   II,     5.  9.  7    |        Ronmark E, Wickens K, Sporik R, Woodfolk JA, Platts-Mills
106   II,     5.  9.  7    |             MA, Silvestri M, Olcese R, Pistorio A, Rossi GA. (
107   II,     5.  9.  7    |           Fabian D, Holt S, Beasley R, Global Initiative for Asthma (
108   II,     5.  9.  7    |            946~ ~To E, Tosca-Segura R, Arn A (2002): Incidence
109   II,     5.  9.  7    |           636~ ~Verlato G, de Marco R (2003): Is the prevalence
110   II,     5. 10.  7    |            10.7. References~ ~Asero R, Ballmer-Weber BK, Beyer
111   II,     5. 10.  7    |         Beyer K, Conti A, Dubakiene R, Fernandez-Rivas M, Hoffmann-Sommergruber
112   II,     5. 10.  7    |          RSH, Stahl Skov P, van Ree R, Vlieg-Boerstra BJ, Hiller
113   II,     5. 10.  7    |           Vlieg-Boerstra BJ, Hiller R, Hourihane JO, Kowalski
114   II,     5. 10.  7    |             50(7):633-637):~ ~Gupta R, Sheikh A, Strachan D, Ross
115   II,     5. 10.  7    |          Knibb RC, Booth DA, Platts R, Booth IW, McDonald A (2005):
116   II,     5. 10.  7    |       Botjes E, Crevel RWR, van Ree R (2007): The prevalence,
117   II,     5. 10.  7    |             62 (7), 717–722.~ ~Rona R, Keil T, Summers C, Gislason
118   II,     5. 10.  7    |            Ciclitira PJ, Van Eckert R, Feighery C, Janssen FW,
119   II,     5. 10.  7    |        Méndez E, Mothes T, Troncone R, Wieser H (2001): Analysis
120   II,     5. 10.  7    |        Bannon G, Cockburn A, Crevel R, Fitzpatrick J, Mills C,
121   II,     5. 11.  3    |         pierced with gold earrings (R Silva et al, 1997). Silver
122   II,     5. 11.  3    |       Alanko K, Harvima RJ, Jolanki R, Kalimo K, Lahti A, Lammintausta
123   II,     5. 11.  3    |    Laukkanen A, luukkaala T, Riekki R, Turjanmaa K, Varjonen E,
124   II,     5. 11.  3    |       Dermatitis, 2003; 49:107108.~R Silva, F Pere a, O Bord o,
125   II,     5. 11.  7    |     Dermatol 2007;25:535-546.~ ~Hay R (2005): Literature review.
126   II,     5. 11.  7    |             371373.~ ~Mar A, Marks R (2000): Prevention of atopic
127   II,     5. 11.  7    |                Weismann K, Krakauer R, Wanscher B (1980): Prevalence
128   II,     5. 15.  6    |             D, Israeli A, Chertkoff R, Zimran A (2006): National
129   II,     7.  7        |             15 April 2008].~ ~Bauer R, Nossek G, Steiner M (2007):
130   II,     7.  7        |            D, Lormand JD, Waxweiler R (Eds.) (2006): Developing
131   II,     8.  2.  1    |           Lennox N, Beange H, Davis R, et al. Management Guidelines –
132   II,     8.  2.  1    |            Tasse, M.J., Thompson, J.R., Verdugo, M-A, Wehmeyer,
133   II,     8.  2.  1    |     Bainbridge D, Cooper S-A, Davis R, Fujiura G, Heller T, Holland
134   II,     8.  2.  1    |             Björkman, M., Ceccotto, R., Kamper, M., Weber, G.,
135   II,     8.  2.  2    |        Pokharel GP, Pararajasegaram R, Etyaale D, Négrel A-D,
136   II,     8.  2.  2    |            Kocur I, Pararajasegaram R, Pokharel GP and Mariotti
137   II,     8.  2.  2    |         Négrel A-D, Pararajasegaram R, Dadzie KY. Global data
138   II,     9.  1.  1    |             registers.~ ~ ~(C=core, R=recommended, F=for further
139   II,     9.  1.  1    |             vital status, plurality~R: Prevalence of selected
140   II,     9.  1.  1    |       selected congenital anomalies~R: Distribution of APGAR score
141   II,     9.  1.  1    |            by age, mode of delivery~R: Maternal mortality by cause
142   II,     9.  1.  1    |         mortality by cause of death~R: Prevalence of severe maternal
143   II,     9.  1.  1    |              Distribution of parity~R: Percentage of women who
144   II,     9.  1.  1    |          who smoke during pregnancy~R: Distribution of mothers’
145   II,     9.  1.  1    |       presentation, prev. Caesarean~R: Percentage of all pregnancies
146   II,     9.  1.  1    |       following fertility treatment~R: Distribution of timing
147   II,     9.  1.  1    |       timing of 1st antenatal visit~R: Distribution of births
148   II,     9.  1.  1    |             mode of onset of labour~R: Distribution of place of
149   II,     9.  1.  1    |      Distribution of place of birth~R: Percentage of infants breast-feeding
150   II,     9.  1.  1    |            186(2):274-8.~Bertollini R, DiLallo D, Spadea T, Perucci
151   II,     9.  1.  1    |             Yang H, Platt RW, Sauve R, Liston R (2000): The contribution
152   II,     9.  1.  1    |           Platt RW, Sauve R, Liston R (2000): The contribution
153   II,     9.  1.  1    |             Yang H, Platt RW, Sauve R, Liston R (2000a): The contribution
154   II,     9.  1.  1    |           Platt RW, Sauve R, Liston R (2000a): The contribution
155   II,     9.  1.  1    |       Cuttini M, Petrou S, Agostino R, et al (2007): Characteristics
156   II,     9.  1.  1    |              Schuitemaker NW, Brand R, van Dongen PW, Bennebroek
157   II,     9.  1.  2    |             LM, Lowry RB, McDonnell R, Metneki J, Poetzsch S,
158   II,     9.  1.  2    |     Gillerot Y, Baguette A, Gjergja R, Barisic I, Christiansen
159   II,     9.  1.  2    |  Steinbicker V, Roesch C, McDonnell R, Scarano G, Calzolari E,
160   II,     9.  1.  2    |    Riano-Galan I, Gatt M, McDonnell R, Nelen V and Stone D (2005c): "
161   II,     9.  1.  2    |             De Walle H, Knill-Jones R, Candela S, Dale I, Danaché
162   II,     9.  1.  2    | Garcia-Minaur S, Physick N, Tenconi R, Wiesel A, Calzolari E,
163   II,     9.  2.  7    |         R.M., Orlos, J.B., Knapp, J.R. (1976): Physical attractiveness,
164   II,     9.  2.  7    |           Fabian D, Holt S, Beasley R (2004?): Global Burden of
165   II,     9.  3.  1    |               McKinlay, J. & Krane, R. (1999) The likely worldwide
166   II,     9.  3.  1    |              Hobbs, F.D.R. Fourcade R. Kiemeney , L, Lee C. and
167   II,     9.  3.  1    |      Osteoporosis in Men. In Kirby, R.S Carson, CC, Kirby, MG &
168   II,     9.  3.  1    |            V Shekelle, P Hopkins Jr R. Forciea, MA Owens, DK (
169   II,     9.  3.  1    |                Verlato G, Calabrese R, De Marco R (2002): (Abstract)
170   II,     9.  3.  1    |            G, Calabrese R, De Marco R (2002): (Abstract) Correlation
171   II,     9.  3.  2    |          186(2):274-8.~ ~Bertollini R, DiLallo D, Spadea T, Perucci
172   II,     9.  3.  2    |             Yang H, Platt RW, Sauve R, Liston R (2000): The contribution
173   II,     9.  3.  2    |           Platt RW, Sauve R, Liston R (2000): The contribution
174   II,     9.  3.  2    |       Cuttini M, Petrou S, Agostino R, et al (2007): Characteristics
175   II,     9.  3.  2    |              Schuitemaker NW, Brand R, van Dongen PW, Bennebroek
176   II,     9.  3.  3    |           al, 2006), Ireland (Layte R et al, 2006) were used,
177   II,     9.  3.  3    |           under 25, it is 17 (Layte R et al, 2006). For what concerns
178   II,     9.  3.  3    |           general population (Layte R et al, 2006).~ ~Predictors
179   II,     9.  3.  3    |            first intercourse (Layte R et all, 2006). In Italy
180   II,     9.  3.  3    |          Roberts C, Morgan A, Smith R, Settertobultr W, Samdal
181   II,     9.  3.  3    |         Wellings K, Weiss HA, Hayes R (2005): Increased condom
182   II,     9.  3.  3    |              Aids 19:1215-23.~Layte R, McGee H, Qual A, Rundle
183   II,     9.  3.  3    |       Donnelly C, Mulcahy F, Conroy R (2006): The Irish Study
184   II,     9.  3.  3    |      Prevention.~Shepherd J, Weston R, Peersman G, Napuli IZ,
185   II,     9.  3.  3    |                 Wilkinson P, French R, Kane R, et al (2006) Teenage
186   II,     9.  3.  3    |         Wilkinson P, French R, Kane R, et al (2006) Teenage conceptions,
187   II,     9.  4.  7    |             618-624(7)~Billings, J. R., Alaszewski A.M., Coxon
188   II,     9.  5.  6    |       Eurostat, UNECE/WHO~ ~Borland R (1990): Slip-ups and relapse
189   II,     9.  5.  6    |        accessed 12.07.07)~ ~Iredale R, Reid A, EIWH (2007): Discrimination
190  III,    10.  1.  3    |       Alcohol 5:373-402.~Beaglehole R (2004): Determinants of
191  III,    10.  1.  3    |          Health. (Edited by: Detels R, McEwen J, Beaglehole R,
192  III,    10.  1.  3    |             R, McEwen J, Beaglehole R, Tanaka H.) New York, Oxford
193  III,    10.  1.  3    |        Burke V, Beilin LJ, Milligan R, Thompson C (1995): Assessment
194  III,    10.  1.  3    |          Health. (Edited by: Detels R, McEwen J, Beaglehole R,
195  III,    10.  1.  3    |             R, McEwen J, Beaglehole R, Tanaka H.) New York, Oxford
196  III,    10.  1.  3    |          Health. (Edited by: Detels R, McEwen J, Beaglehole R,
197  III,    10.  1.  3    |             R, McEwen J, Beaglehole R, Tanaka H.) New York, Oxford
198  III,    10.  1.  3    |            Lindenberg CS, Solorzano R, Kelley M, Darrow V, Gendrop
199  III,    10.  1.  3    |             Rehm J, Ashley MJ, Room R, Single E, Bondy S, Ferrence
200  III,    10.  1.  3    |         Single E, Bondy S, Ferrence R, Giesbrecht N (1996): On
201  III,    10.  1.  3    |             41(4):455-463.~Velleman R (1992a): Intergenerational
202  III,    10.  1.  3    |             27(3):253-280.~Velleman R (1992b): Intergenerational
203  III,    10.  2.  1    |             Dicato M, Diehl L, Doll R, Franceschi S, Gillis CR,
204  III,    10.  2.  1    |            AE, Geurts JJM, Crialesi R, Grötvedt L (2000): Educational
205  III,    10.  2.  1    |        Janson C, Künzli N, de Marco R, Chinn S, Jarvis D, Svanes
206  III,    10.  2.  1    |          Svanes C, Heinrich J, Jõgi R, Gislason T, Sunyer J, Ackermann-Liebrich
207  III,    10.  2.  1    |           Available at: htt ~ ~Peto R, Lopez AD, Boreham J, Thun
208  III,    10.  2.  1    |     Prevention.~ ~Babor TF, Caetano R, Casswell S, Edwards G,
209  III,    10.  2.  1    |            Hill L, Holder HD, Homel R, Österberg E, Rehm J, Room
210  III,    10.  2.  1    |           Österberg E, Rehm J, Room R and Rossow I (2003): Alcohol:
211  III,    10.  2.  1    |        Shults RA, Sleet DA, Compton R, Nichols JL (2005): Effectiveness
212  III,    10.  2.  1    |      Journal, 316: 1636-42.~ ~Ljung R, Peterson S, Hallqvist J,
213  III,    10.  2.  1    |             Brettschneider WD, Naul R (2004): Study on young people’
214  III,    10.  2.  1    |             2):260275.~ ~Sonstroem R (1984): Exercise and self-esteem.
215  III,    10.  2.  1    |         Madrid . Requejo A., Ortega R. 2002~Sweden~Dietary habits
216  III,    10.  2.  1    |             1472.~ ~Boros J, Németh R, Vitrai J (2002): Országos
217  III,    10.  2.  1    |          Roberts C, Morgan A, Smith R, Settertobulte W, Samdal
218  III,    10.  2.  1    |         Reviews 7:233-237.~ ~Dolman R, Kingdon A, Roberts C, eds (
219  III,    10.  2.  1    |             V, Paalanen L, Prättälä R (2007): Suaugusių lietuvos
220  III,    10.  2.  1    |      Helakorpi S, Patja S, Prättälä R, Uutela A (2007): Suomalaisen
221  III,    10.  2.  1    |            James WPT, Jackson-Leach R,  Mhurchu C, Kalamara
222  III,    10.  2.  1    |             Yang H, Platt RW, Usher R, McNamara H, Joseph KS,
223  III,    10.  2.  1    |            Lobstein T, Baur L, Uauy R, for the IASO International
224  III,    10.  2.  1    |             V, Paalanen L, Prättälä R (2005): Latvijas iedzïvotäju
225  III,    10.  2.  1    |          Hermann D, Boros J, Németh R, Kéki Z (2005): Táplálkozási
226  III,    10.  2.  1    |         Primatesta P, Chinn S, Rona R, Falascheti E (2005): Overweight
227  III,    10.  2.  1    |              Trichopoulou A, Tumino R, Navarro Sanchez C, Martinez
228  III,    10.  2.  1    |             Pettersson U, Palmqvist R, Van Guelpen B, Bingham
229  III,    10.  2.  1    |            Pala V, Masala G, Tumino R, Sacerdote C, Del Pezzo
230  III,    10.  2.  1    |            Welch AA, Krogh V, Luben R, Allen N, Overvad K, Tjonneland
231  III,    10.  2.  1    |          Janzon L, Jansson J, Luben R, Spencer EA, Overvad K,
232  III,    10.  2.  1    |             V, Zavitsanos X, Tumino R, Galasso R, Bueno-De-Mesquita
233  III,    10.  2.  1    |     Zavitsanos X, Tumino R, Galasso R, Bueno-De-Mesquita HB, Ocke
234  III,    10.  2.  4    |        Schröder P, Brand H, Zimmern R (2006): Getting Ready for
235  III,    10.  2.  4    |           Chakravarti A., Gesteland R, Walters L (1998): New Goals
236  III,    10.  2.  4    |          317.~ ~Lunshof JE, Chadwik R, Vorhaus DB, Church GM (
237  III,    10.  2.  4    |            nrg2360: 2-7.~ ~Roberts, R, Sullivan P, Joyce P, Kennedy
238  III,    10.  2.  4    |             Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson
239  III,    10.  2.  5    |          Puura K, Luoma I, Salmelin R, Davis H, Tsiantis J, Ispanovic-Radojkovic
240  III,    10.  2.  5    |  Paradisiotou A, Vizakou S, Roberts R, Cox A, Day C (2002) The
241  III,    10.  3.  1    |      Tampere, 2006.~Bray F, Sankila R, Ferlay J, Parkin DM (2002):
242  III,    10.  3.  1    |           Bochicchio F, Deo H, Falk R, Forastiere F, Hakama M,
243  III,    10.  3.  1    |        Whitley E, Wichmann HE, Doll R, (2005): Radon in homes
244  III,    10.  3.  1    |             92, no. 4, 371-8.~Lucas R, McMichael T, Smith W, Armstrong
245  III,    10.  3.  1    |            Med., 49, 266-274.~Torfs R (2003). Kwantificering van
246  III,    10.  3.  1    |    Villeneuve PJ, Morrison HI, Lane R (2007). Radon and lung cancer
247  III,    10.  3.  2    |        Morrison, S Rauch, C McLeod, R Ma, S Caroli, A Alimonti,
248  III,    10.  3.  2    |               Ravindra, K, L Bencs, R van Grieken (2004): Platinum
249  III,    10.  3.  2    |                   Vieth B, Rüdiger, R, Ostermann, B, Mielke, H. (
250  III,    10.  4.  2    |          2005. pp.286.~ ~Kallenborn R. (2006): Persistent organic
251  III,    10.  4.  2    |            Inoue, K, Okada, F, Ito, R, Kato, S, Sasaki, S, Nakajima,
252  III,    10.  4.  2    |             F, Yoshimura, Y, Kishi, R, Nakazawa, H.(2004). Perfluorooctane
253  III,    10.  4.  2    |             1204-1207~ ~Kallenborn, R. and A. DiGuardo (2006).
254  III,    10.  5.  1    |            Kim HS, Mccarthy H, Oren R, Finzi C, EllsWorth DS,
255  III,    10.  5.  1    |             569.~Milstead TM, Miles R, Röbbel N. (2006): Housing
256  III,    10.  5.  1    |         Richardson G, Eick S, Jones R (2005): How is the indoor
257  III,    10.  5.  1    |      children (1257-RP).~ ~Walinder R, Gunnarsson K, Runeson R,
258  III,    10.  5.  1    |            R, Gunnarsson K, Runeson R, Smedje G (2007) Physiological
259  III,    10.  5.  3    |             Geneva. htt tm~Karasek, R. A. & Theorell, T. (1990).
260  III,    10.  5.  3    |            Leal J, Luengo-Fernandez R, Gray A, Peterson S, Rayner
261  III,    10.  6.  1    |          Godeau E, Roberts C, Smith R, Currie D, Picket W, Richter
262  III,    10.  6.  1    |    Catalogue/20080617_1.~ ~De Vogli R, Chandola T, Marmot MG (
263  III,    10.  6.  1    |            128(2):370-80.~ ~Kessler R, McLeod J, Wethington E.
264  III,    10.  6.  1    |            1017~Van Dijk J, Manchin R, Van Kesteren J, Hideg G,
265   IV,    11.  5.  6    |   substances~ ~· Recommendation No. R (99) 21 of the Committee
266   IV,    11.  5.  6    |           and to Recommendation No. R (97) 5 on the protection
267   IV,    11.  6.  5    |      References~ ~Altman S, Blendon R Eds. (1979): Medical Technology:
268   IV,    11.  6.  5    |         Printing Office.~ ~Anderson R (2004): Health and health
269   IV,    11.  6.  5    |            Public Health.~ ~Blendon R, Kim M, Benson JM (2001): "
270   IV,    11.  6.  5    |        Health 13(1): 13-16.~ ~Brook R, McGlynn E et al. (1996): "
271   IV,    11.  6.  5    |           Oncol 22: 2000-7.~ ~Busse R, Schreyogg J et al. (2006): "
272   IV,    11.  6.  5    |         Science 9: 211-213.~ ~Busse R, Orvain J, Velasco M, Perleth
273   IV,    11.  6.  5    |             Practice. K. Walshe and R. Boaden. Berkshire, Open
274   IV,    11.  6.  5    |            350(4): 406-410.~ ~Ervik R (1998): The Redistributive
275   IV,    11.  6.  5    |          systems in Western Europe. R. B. Saltman, R. Busse and
276   IV,    11.  6.  5    |      Western Europe. R. B. Saltman, R. Busse and J. Figueras.
277   IV,    11.  6.  5    |          systems in Western Europe. R. B. Saltman, R. Busse and
278   IV,    11.  6.  5    |      Western Europe. R. B. Saltman, R. Busse and J. Figueras.
279   IV,    11.  6.  5    |             Practice. K. Walshe and R. Boaden. Berkshire, Open
280   IV,    11.  6.  5    |       health care reform in Europe. R. B. Saltman, J. Figueras
281   IV,    11.  6.  5    |         University Press.~ ~Richman R, Lancaster DR (2000): "The
282   IV,    11.  6.  5    |            5): 1589-606.~ ~Robinson R, Jakubowski E et al. (2005):
283   IV,    11.  6.  5    |           performance. J. Figueras, R. Robinson and E. Jakubowski.
284   IV,    11.  6.  5    |         Rosenthal MB, Fernandopulle R et al. (2004): "Paying for
285   IV,    11.  6.  5    |          systems in Western Europe. R. B. Saltman, R. Busse and
286   IV,    11.  6.  5    |      Western Europe. R. B. Saltman, R. Busse and J. Figueras.
287   IV,    11.  6.  5    |           320: 774-77.~ ~Westerling R (1996): “Studies of avoidable
288   IV,    11.  6.  5    |        Assessment 1(Doc09).~ ~Kane, R. L. (1997). Understanding
289   IV,    11.  6.  5    |              Vaughan, J.P., Morrow, R.H. Manual of Epidemiology
290   IV,    13.  7.  2    |     expanding private investment in R&D; location advantages for
291   IV,    13.  7.  2    |             location advantages for R&D and production facilities;
292   IV,    13.  9        |       Köhler LI, Blair ME, Mechtler R (2003): Child Health Indicators